Agennix AG is a publicly traded biopharmaceutical company focused on developing novel anti-cancer therapies.  The Company was formed by the combination of GPC Biotech AG and Agennix Incorporated.  The Company’s most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for wound healing.  Agennix is a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas.
 

http://www.agennix.com